GeneDx and Prognos Health have entered a strategic collaboration to help patients with rare diseases gain access to potential treatments quickly.
The parties will leverage real-world data to reduce treatment journeys for such patients.
Go deeper with GlobalData
The partnership will assist life science firms in utilising a complete de-identified dataset specific to rare diseases to expedite access to life-saving treatments.
The Prognos marketplace will integrate the de-identified rare disease data of GeneDx.
This dataset will comprise routinely updated information as GeneDx continues to include fresh genomic and health data collected using its complete genome and exome sequencing tests.
See Also:
Biopharma companies that collaborate with Prognos will subsequently receive automatic alerts on clinicians diagnosing new patients who could benefit from treatments that are approved by the US Food and Drug Administration (FDA).
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataGeneDx chief transformation officer Kareem Saad stated: “Patients with rare diseases oftentimes have to endure a diagnostic odyssey of approximately eight years, meaning that not months, but years are wasted without an accurate diagnosis and without knowledge of or access to an FDA-approved therapy.
“GeneDx is dedicated to ending the diagnostic odyssey for patients and their families, and this partnership gives us the opportunity to go a step further to connect clinicians and their patients with rare diseases to appropriate treatment options and ultimately improve health and health economic outcomes.”
